These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19905999)

  • 1. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.
    Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
    Gynecol Endocrinol; 2009 Dec; 25(12):799-806. PubMed ID: 19905999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
    Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Is the assessment of biological activity of prolactin essential in the diagnosis of hyperprolactinemia?].
    Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
    Pol Merkur Lekarski; 2010 May; 28(167):359-61. PubMed ID: 20568397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovary syndrome or hyperprolactinaemia: a study of mild hyperprolactinaemia.
    Su HW; Chen CM; Chou SY; Liang SJ; Hsu CS; Hsu MI
    Gynecol Endocrinol; 2011 Jan; 27(1):55-62. PubMed ID: 20504100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyperprolactinemia and disorders of the menstrual cycle].
    Topalski-Fistes N; Bujas M; Maticki-Sekulić M; Suvacarev S
    Med Pregl; 1999; 52(3-5):156-61. PubMed ID: 10518402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients.
    Lu CC; Hsieh CJ
    Kaohsiung J Med Sci; 2012 Feb; 28(2):94-9. PubMed ID: 22313536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of latent hyperprolactinaemia on the levels of LH, FSH, E2 and T in the midfollicular phase of the cycle.
    Kostál M; Tosner J
    Arch Gynecol Obstet; 1997; 259(2):65-8. PubMed ID: 9059746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprolactinaemia in polycystic ovary syndrome.
    Lunde O
    Ann Chir Gynaecol; 1981; 70(4):197-201. PubMed ID: 6797343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
    Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
    Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum retinol-binding protein 4 levels in nonobese women with polycystic ovary syndrome.
    Chan TF; Tsai YC; Chiu PR; Chen YL; Lee CH; Tsai EM
    Fertil Steril; 2010 Feb; 93(3):869-73. PubMed ID: 19028383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Hsu MI; Liou TH; Liang SJ; Su HW; Wu CH; Hsu CS
    Fertil Steril; 2009 Apr; 91(4):1168-74. PubMed ID: 18325508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistically significant changes of antimüllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women.
    Wunder DM; Bersinger NA; Yared M; Kretschmer R; Birkhäuser MH
    Fertil Steril; 2008 Apr; 89(4):927-33. PubMed ID: 17603052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
    Song J; Shen H; Li J; Huang Z; Zhang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
    Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
    Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular heterogeneity of prolactin and gonadotropins in some forms of sterility].
    Morán C; Fonseca ME; Ochoa R; Masón M; Gama R; Zárate A
    Ginecol Obstet Mex; 1990; 58 Suppl 1():9-13. PubMed ID: 2125965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of metergoline on prolactin, follicle stimulating hormone, luteinizing hormone and thyroid stimulating hormone response to TRH and LHRH in normal men and women.
    Sartani A; de Pasqua A; Cesati R; Farina L; Pontiroli AE
    Horm Metab Res; 1984 Oct; 16(10):535-8. PubMed ID: 6437954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Wujijing Oral Liquid on menstrual disturbance of women.
    Geng SS; Li HZ; Wu XK; Dang JM; Tong H; Zhao CY; Liu Y; Cai YQ
    J Ethnopharmacol; 2010 Apr; 128(3):649-53. PubMed ID: 20051257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum resistin levels in women with polycystic ovary syndrome.
    Panidis D; Koliakos G; Kourtis A; Farmakiotis D; Mouslech T; Rousso D
    Fertil Steril; 2004 Feb; 81(2):361-6. PubMed ID: 14967374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.